Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway
FDI resulted in cost savings and improved quality-adjusted life expectancy versus FCM in patients with IDA and IBD in Norway. FDI therefore represents the economically preferable iron formulation in Norwegian patients with IBD and IDA in whom it is indicated.
Authors
- Neesha Nanu (ORCID: https://orcid.org/0000-0002-3817-3463)
- Erik Jørgensen (ORCID: https://orcid.org/0000-0003-1538-8565)
- Richard Fulton Pollock (ORCID: https://orcid.org/0000-0002-9873-7507)
- Trond Espen Detlie (ORCID: https://orcid.org/0000-0002-1576-5298)
- Lars Karlsen
Institutions
- Stavanger University Hospital (NO)
- Akershus University Hospital (NO)
- A-T Society (GB)
- Covalence Research
- Amec Foster Wheeler (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1080/13696998.2024.2444833
- Citations
- 2
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Pfizer
- Vifor Pharma